Skip to content

Study on the efficacy observation and dose-effect relationship of acupuncture at Jingxue points combined with transcranial magnetic stimulation in the treatment of mild cognitive impairment in the elderly

Study on the efficacy observation and dose-effect relationship of acupuncture at Jingxue points combined with transcranial magnetic stimulation in the treatment of mild cognitive impairment in the elderly

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001371
Enrollment
Unknown
Registered
2025-07-09
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment

Interventions

Wellhole Needling Group:Acupuncture for the patient at Shaoshang Shangyang Zhongchong Guanchong and Shaochong 3 times a week for a total of 12 sessions continuous treatment for 1 month.
Jing well-acupuncture combined with high-frequency transcranial magnetic stimulation group:The combination of acupuncture at the acupuncture points and transcranial magnetic stimulation with the frequ
Jing well-point acupuncture combined with low-frequency transcranial magnetic stimulation group:The combination of acupuncture at the acupuncture points and transcranial magnetic stimulation with the
Jing well-point acupuncture combined with medium-frequency transcranial magnetic stimulation group:The combination of acupuncture at the acupuncture points and transcranial magnetic stimulation with t
Transcranial magnetic stimulation group:Transcranial magnetic stimulation targets the left dorsolateral prefrontal cortex of the patient. The treatment parameters are as follows: 10 Hz resting motor t

Sponsors

Nanchang Hongdu Hospital of TraditionalChinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for amnestic mild cognitive impairment; (2) No gender restrictions age between 55-75 years; (3) The main complaint includes a subjective feeling of memory decline; (4) Objective tests show memory decline and cognitive changes: Montreal Cognitive Assessment (MOCA) score < 26 with an additional point if the years of education = 12; Mini-Mental State Examination (MMSE) score < 24. AVLT score is below 5 standard deviations adjusted for age and education (55-59 = 4 60-69 = 3 70-75 = 2); (5) Clinical Dementia Rating (CDR) score is 5 or Global Deterioration Scale (GDS) score is 2 or 3. Does not meet the diagnostic criteria for dementia as defined by the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Revised (DSM-IV-R) of the American Psychiatric Association; (6) Activities of Daily Living (ADL) assessment shows basic normal daily living ability and intact independent living function; (7) Has not used medications to improve cognitive or motor disorders; (8) The patient has signed an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Hachinski Ischemia Scale (HIS) score > 4 points;(2) Cognitive impairment caused by other reasons: cerebrovascular disease central nervous system infections Creutzfeldt-Jakob disease Huntington's disease and Parkinson's disease Lewy body dementia traumatic brain injury dementia other physical and chemical factors (medications alcohol carbon monoxide etc.) significant somatic diseases (hepatic encephalopathy pulmonary encephalopathy) intracranial occupying lesions (subdural hematoma brain tumors) endocrine system disorders (thyroid diseases parathyroid diseases) and dementia caused by vitamin or other cognitive reasons;(3) Patients with psychiatric disorders that meet DSM-IV criteria for schizophrenia or other mental illnesses bipolar disorder major depression or delirium; (Hamilton Anxiety Scale (HAMA) assessed score > 6: Hamilton Depression Scale (HAMD) 21-item assessment score > 8);(4) Presence of irreversible visual or auditory impairments preventing completion of scales and relevant tests.

Design outcomes

Primary

MeasureTime frame
Aß42 Aß40 Aß42/Aß40 p-tau181;functional near-infrared spectroscopy;Montreal Cognitive Assessment;(Mini-mentalState Examination;

Countries

CHINA

Contacts

Public ContactWu Dan

Nanchang Hongdu Hospital of TraditionalChinese Medicine

wd995318069@163.com15970655877

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026